CXCL6 was identified as a potential predictive biomarker for hepatocellular carcinoma patients undergoing trans arterial chemoembolization in Kinzler et al. (2023); CXCL6 is an inflammatory chemokine that plays a crucial role in immune response and cancer progression. This evidence concerns the gene CXCL6 and hepatocellular carcinoma.